PAM
NVO

Palisade Asset Management’s Novo Nordisk NVO Stock Holding History

Palisade Asset Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,974
Closed -$110K – 512
2025
Q3 		$110K Buy
+1,974
New +$116K 0.01% 228
2024
Q4 		– Sell
-2,296
Closed -$273K – 198
2024
Q3 		$273K Sell
2,296
-350
-13% -$46.7K 0.03% 181
2024
Q2 		$378K Sell
2,646
-490
-16% -$64.9K 0.04% 166
2024
Q1 		$403K Sell
3,136
-382
-11% -$45.5K 0.04% 165
2023
Q4 		$364K Buy
3,518
+382
+12% +$37.8K 0.04% 162
2023
Q3 		$285K Hold
3,136
– – 0.03% 165
2023
Q2 		$254K Hold
3,136
– – 0.03% 172
2023
Q1 		$250K Hold
3,136
– – 0.03% 167
2022
Q4 		$212K Buy
+3,136
New +$184K 0.02% 182

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Palisade Asset Management's NVO Position: Q4 2025 in Review

Palisade Asset Management sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 1,974 shares — an estimated $110K sold.

Palisade Asset Management first reported a position in NVO in Q4 2022 and held it in 9 quarters. The position peaked at $403K in Q1 2024. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Palisade Asset Management reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Palisade Asset Management sold 1,974 Novo Nordisk shares in Q4 2025, an estimated $110K.
  • Palisade Asset Management first reported a position in Novo Nordisk in Q4 2022 and held it in 9 quarters.
  • Palisade Asset Management's Novo Nordisk position peaked at $403K in Q1 2024.
  • 1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Palisade Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.